BioNTech aims to have multiple commercialised cancer drugs by 2030 as the company continues its pivot away from Covid-19 vaccines.
Speaking at the J.P. Morgan Healthcare Conference in San Francisco, taking place from 12 to 15 January, BioNTech CEO Ugur Sahin said: “Our ambition is to build a fully integrated multiproduct oncology company, and 2026 is just the beginning of our road map.”
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
BioNTech became a well-established company in the pharmaceutical sector after co-developing the first mRNA Covid-19 vaccine with Pfizer. Amid waning demand for Covid-19 products, however, BioNTech’s share price is currently trading around 77% lower compared to its all-time high share price in August 2021.
While the Germany-headquartered company will still make adaptive Covid-19 vaccines as new infectious seasons arrive, Sahin is overseeing a significant strategic pivot to oncology in a bid to boost revenues.
BioNTech currently has more than 25 Phase II and III programmes across oncology and 10 novel-combination trials. Modalities in its cancer pipeline include next generation immunomodulators, antibody drug conjugates (ADCs), and mRNA cancer immunotherapies.
Sahin has high hopes for candidates in the renewed pipeline. For example, the company believes pumitamig – a PD-L1/VEGF bispecific antibody – has the potential to become the next-generation immune-oncology standard of care across multiple cancer indications. In June 2025, Bristol Myers Squibb (BMS) signed a deal worth up to $11bn with BioNTech to co-develop pumitamig. Gotistobart, BioNTech’s anti-CTLA-4 for lung cancer, is also at the forefront of BioNTech’s pipeline, having demonstrated success in a Phase III trial.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSome of BioNTech’s ADC candidates are also being developed for a pan-tumour strategy, while other drugs are being evaluated in specific indications. For example, individualised mRNA vaccines are being tested in pancreatic cancer, bladder cancer, and colorectal cancer. BioNTech bolstered its mRNA pipeline with a $1.25bn acquisition of CureVac in June 2025.
Reacting to BioNTech’s session in San Francisco, Citi analysts said: “We continue to like the cadence and quality of data coming from the late-stage pipeline and see the company as a differentiated play among traditional vaccine names as it continues its transformation into a commercial oncology company, which should serve to more than offset downsides from vaccine volatility.”
Pumitamig is one of five late-stage readouts slated to arrive in 2026 as BioNTech enters a data-heavy few years. During this hive of R&D and clinical activity, the company is also ramping up its commercial framework.
“We are entering a phase of sustained clinical data output from 2026 to 2029, and we will provide regular updates on execution and progress. This pipeline supports multiple approval opportunities, and we are building launch readiness now, developing indication-specific expertise and advancing market access capabilities in the tumour types where we anticipate first launches,” Sahin commented.
“For 2030, we expect that BioNTech will be a diversified multiproduct technology company,” he affirmed.
In November, BioNTech increased its 2025 revenue guidance and ended the year with more than $17bn in cash and cash equivalents and securities. Chief financial officer (CFO) Ramón Zapata-Gomez said that the company would prioritise investing in its internal pipeline, but did not rule out acquisitions and collaborations as a second deployment of resources.
Sign up here to receive daily updates on the latest healthcare industry trends emerging from the JP Morgan Healthcare Conference 2026. Sign up here to receive a comprehensive report after the conference.
